Date: 15 – 16 November 2021
Venue: Lyon, France
Last year, VOXCAN was fully involved to help combat COVID-19 by proposing easy-to handle small animal model for the development of vaccines and therapies against SARS-CoV-2. About 20 studies have been to support the development of vaccines and therapies based on very different approaches.
This year VOXCAN has the great honor to give a talk at I4ID on a therapeutic approach in K18-hACE2 mouse model. This innovative therapeutic approach has significantly reduced the weight loss associated with the infection from 3 to 5 dpi.In addition, a single administration of the evaluated therapy allowed to reduce the viral load at 2 dpi and 5 dpi. Finally, the viral titer in lungs, evaluated by plaque assay, was also reduced by the treatment.
Moreover, VOXCAN has been invited to participate in a collaborative work with BIOASTER to strengthen the Syrian golden hamster model infected with SARS-CoV-2 virus strain by intra-nasal (i.n.) instillation. At this event VOXCAN and BIOASTER present you on a poster our SARS-CoV-2 infected Syrian golden hamster model as well as a panel of obtained readouts including body weight, histopathology, virus detection by PFU and RT-qPCR, cytokines monitoring and neutralization assays, over 14 days !
VOXCAN invites you to join us at I4ID event to learn more about our internal capabilities for SARS-CoV-2 infected models. Click on the button below !
#Preclinical #CRO #invivo #efficacy #biodistribution #tolerability #immunotherapies #infectiousdiseases #vaccines #SARSCoV2 #COVID19 #imaging #bioluminescence #fluorescence
